Field & Main Bank acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the first quarter, HoldingsChannel reports. The institutional investor acquired 2,515 shares of the medical research company’s stock, valued at approximately $688,000.
A number of other large investors have also bought and sold shares of the business. Creative Planning grew its stake in Thermo Fisher Scientific by 2.4% in the first quarter. Creative Planning now owns 29,120 shares of the medical research company’s stock valued at $7,971,000 after acquiring an additional 674 shares during the period. Steinberg Global Asset Management grew its stake in Thermo Fisher Scientific by 27.7% in the first quarter. Steinberg Global Asset Management now owns 6,064 shares of the medical research company’s stock valued at $1,660,000 after acquiring an additional 1,317 shares during the period. S&CO Inc. grew its stake in Thermo Fisher Scientific by 0.5% in the first quarter. S&CO Inc. now owns 50,139 shares of the medical research company’s stock valued at $13,724,000 after acquiring an additional 237 shares during the period. Harvest Management LLC grew its stake in Thermo Fisher Scientific by 60.9% in the first quarter. Harvest Management LLC now owns 2,700 shares of the medical research company’s stock valued at $739,000 after acquiring an additional 1,022 shares during the period. Finally, Exane Derivatives grew its stake in Thermo Fisher Scientific by 99.4% in the first quarter. Exane Derivatives now owns 347 shares of the medical research company’s stock valued at $95,000 after acquiring an additional 173 shares during the period. 88.67% of the stock is owned by hedge funds and other institutional investors.
In related news, CAO Peter E. Hornstra sold 5,920 shares of the company’s stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $250.00, for a total transaction of $1,480,000.00. Following the sale, the chief accounting officer now owns 17,057 shares in the company, valued at $4,264,250. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gregory J. Herrema sold 3,299 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $263.05, for a total value of $867,801.95. The disclosure for this sale can be found here. Insiders have sold 36,927 shares of company stock worth $9,388,124 in the last quarter. 0.49% of the stock is currently owned by corporate insiders.
TMO has been the subject of a number of research analyst reports. Bank of America reissued a “buy” rating and issued a $300.00 target price (up from $285.00) on shares of Thermo Fisher Scientific in a research note on Tuesday, April 16th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $310.00 target price for the company in a research note on Tuesday, April 9th. BTIG Research upped their price objective on Thermo Fisher Scientific to $310.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th. UBS Group upped their price objective on Thermo Fisher Scientific to $305.00 and gave the stock a “buy” rating in a research report on Monday, March 25th. Finally, Deutsche Bank upped their price objective on Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus price target of $293.33.
TMO stock opened at $273.22 on Monday. The company has a quick ratio of 1.24, a current ratio of 1.69 and a debt-to-equity ratio of 0.61. The stock has a market cap of $109.02 billion, a PE ratio of 24.57, a PEG ratio of 1.80 and a beta of 1.13. Thermo Fisher Scientific Inc. has a fifty-two week low of $202.83 and a fifty-two week high of $282.98.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.74 by $0.07. The company had revenue of $6.13 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Thermo Fisher Scientific had a return on equity of 17.06% and a net margin of 12.89%. Thermo Fisher Scientific’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.50 earnings per share. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 12.18 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, April 16th. Investors of record on Friday, March 15th were issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. Thermo Fisher Scientific’s dividend payout ratio is presently 6.83%.
TRADEMARK VIOLATION WARNING: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://transcriptdaily.com/2019/04/29/field-main-bank-acquires-new-holdings-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Read More: Cost of equity and a company’s balance sheet
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.